![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
B Gasnier, MP Roisin, D Scherman, S Coornaert, G Desplanches and JP Henry
meta-Iodobenzylguanidine, an adrenal imaging agent used for the scintigraphic detection of human pheochromocytoma, is a substrate for the monoamine uptake system of chromaffin granules. It is accumulated by bovine chromaffin granule membrane vesicles in the presence of ATP, and it can be released by an osmotic shock. The uptake is dependent upon the generation of an H+-electrochemical gradient by an ATP- dependent H+ pump since it is blocked by an H+ ionophore and since meta- iodobenzylguanidine uptake can be driven by imposing an artificial pH gradient (inside acidic) on the membrane vesicles. The transport is saturable and its Km value (2.0 microM at pH 8.0) is similar to that of noradrenaline (5.3 microM). Transport occurs through the monoamine transporter since it is blocked by the same inhibitors, tetrabenazine and reserpine, and also by the transporter substrates noradrenaline and serotonin. Noradrenaline inhibits meta-iodobenzylguanidine uptake competitively (Ki = 13 microM). In addition, meta-iodobenzylguanidine displaces dihydrotetrabenazine and reserpine from their binding sites on chromaffin granule membranes. It is thus likely that, after in vivo administration, [131I] meta-iodobenzylguanidine is ultimately stored in chromaffin granules and that it is translocated by the monoamine transporter.
This article has been cited by other articles:
|
|
 |
|
  T.-T. Huynh, K. Pacak, F. M Brouwers, M. S Abu-Asab, R. A Worrell, M. M Walther, A. G Elkahloun, D. S Goldstein, S. Cleary, and G. Eisenhofer Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 Eur. J. Endocrinol., October 1, 2005; 153(4): 551 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pop-Busui, I. Kirkwood, H. Schmid, V. Marinescu, J. Schroeder, D. Larkin, E. Yamada, D. M. Raffel, and M. J. Stevens Sympathetic dysfunction in type 1 diabetes: Association with impaired myocardial blood flow reserve and diastolic dysfunction J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2368 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, T. Ishikawa, S. Ichikawa, T. Suzuki, and M. Kurabayashi Effects of Intravenous Atrial Natriuretic Peptide on Cardiac Sympathetic Nerve Activity in Patients with Decompensated Congestive Heart Failure J. Nucl. Med., July 1, 2004; 45(7): 1108 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy J. Am. Coll. Cardiol., February 19, 2003; 41(4): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Spironolactone Improves Cardiac Sympathetic Nerve Activity and Symptoms in Patients with Congestive Heart Failure J. Nucl. Med., October 1, 2002; 43(10): 1279 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Ogita, T Shimonagata, M Fukunami, K Kumagai, T Yamada, Y Asano, A Hirata, M Asai, H Kusuoka, M Hori, et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study Heart, December 1, 2001; 86(6): 656 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. PARSONS Transport mechanisms in acetylcholine and monoamine storage FASEB J, December 1, 2000; 14(15): 2423 - 2434. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Yoshita and S. Braune Cardiac uptake of [123I]MIBG separates PD from multiple system atrophy Neurology, May 9, 2000; 54(9): 1877 - 1878. [Full Text] [PDF]
|
|
|
|
|
|
S. Braune, M. Reinhardt, R. Schnitzer, A. Riedel, and C. H. Lucking Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy Neurology, September 1, 1999; 53(5): 1020 - 1020. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. K. Sievert and A. E. Ruoho Peptide Mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-Iodo-4'-azidophenyl)propionyl]tetrabenazine Binding Sites for the Synaptic Vesicle Monoamine Transporter J. Biol. Chem., October 10, 1997; 272(41): 26049 - 26055. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
